News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
CSPC PHARMA Announces Phase III Clinical Results of KN026 Plus Docetaxel for Injection Presented as LBA Oral Report at ASCO in US
CSPC PHARMA (01093.HK) announced that the results of the Phase III clinical study (Study No.: KN026–004/Neo-Healer) of the HER2 bispecific antibody Anbenitamab (brand name: E...
Reset
Send
The window will close in 5 seconds
CSPC PHARMA Announces Phase III Clinical Results of KN026 Plus Docetaxel for Injection Presented as LBA Oral Report at ASCO in US
Close
Recommend
12
Positive
19
Negative
4
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get 1 Intel/Selected Gold ETF share!

CSPC PHARMA (01093.HK)  -0.320 (-4.227%)    Short selling $210.03M; Ratio 23.438%   announced that the results of the Phase III clinical study (Study No.: KN026–004/Neo-Healer) of the HER2 bispecific antibody Anbenitamab (brand name: Ennituo (KN026), co-developed by Shanghai JMT-BIO Technology Co., Ltd., a subsidiary of the Company, and Jiangsu Alphamab Biopharmaceuticals Co., Ltd., in combination with the Group’s self-developed Docetaxel for Injection (Albuminbound) (HB1801) for the neoadjuvant treatment of HER2-positive breast cancer, have been selected for a Late-Breaking Abstract (LBA) oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-06-03 16:25.)

Related News CLSA: CSPC PHARMA (01093.HK) 1Q26 Beats; Reiterate "Conviction List Outperform" with TP HKD19

Auto-translated by AI
View Original Text
This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.